CORT logo

Corcept Therapeutics Incorporated (CORT)

$69.22

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CORT

Market cap

$7.58B

EPS

1.27

P/E ratio

288.5

Price to sales

15.77

Dividend yield

--

Beta

0.537523

Price on CORT

Previous close

$72.94

Today's open

$72.31

Day's range

$68.63 - $72.62

52 week range

$28.66 - $126.38

Profile about CORT

CEO

Joseph K. Belanoff

Employees

730

Headquarters

Redwood City, CA

Exchange

NASDAQ Capital Market

Shares outstanding

109443109

Issue type

Common Stock

CORT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CORT

ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulva.

news source

Business Wire • Nov 16, 2026

news preview

CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.

news source

MarketBeat • Nov 4, 2026

news preview

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of the importance of diagnosing and treating patients with Cushing's syndrome is steadily increasing and is driving the.

news source

Business Wire • Nov 3, 2026

news preview

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.

news source

Business Wire • Oct 27, 2026

news preview

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company's Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant.

news source

Business Wire • Oct 26, 2026

news preview

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.

news source

Business Wire • Oct 20, 2026

news preview

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.

news source

Zacks Investment Research • Oct 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Corcept Therapeutics Incorporated

Open an M1 investment account to buy and sell Corcept Therapeutics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CORT on M1